Nasdaq Apls News Today

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) shares fell 3.5% during trading on Monday after Mizuho lowered their price target on the stock from $60.00 to $52.00. Mizuho currently has a neutral rating on the stock. Apellis Pharmaceuticals traded as low as $48.01 and last traded at $48.11. 88,800 shares changed hands during trading, […]

HC Wainwright reaffirmed their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) in a report released on Friday, Benzinga reports. The firm currently has a $92.00 target price on the stock. Other equities research analysts have also recently issued research reports about the company. UBS Group upped their target price on Apellis […]

Xponance Inc. reduced its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 6.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,927 shares of the company’s stock after selling 939 shares during the quarter. Xponance Inc.’s holdings in Apellis Pharmaceuticals […]

WALTHAM, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference...

Jennison Associates LLC reduced its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 7.5% in the fourth quarter, Holdings Channel reports. The firm owned 3,275,922 shares of the company’s stock after selling 266,287 shares during the period. Jennison Associates LLC’s holdings in Apellis Pharmaceuticals were worth $196,097,000 at the end of […]

Jennison Associates LLC lessened its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 7.5% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 3,275,922 shares of the company’s stock after selling 266,287 shares during the period. Jennison Associates LLC owned 2.76% of Apellis Pharmaceuticals […]

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price objective decreased by Wedbush from $67.00 to $57.00 in a report issued on Wednesday morning, Benzinga reports. Wedbush currently has a neutral rating on the stock. Wedbush also issued estimates for Apellis Pharmaceuticals’ Q1 2024 earnings at ($0.83) EPS, Q4 2024 earnings at ($0.27) EPS, FY2024 […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report)’s share price fell 3.3% during mid-day trading on Monday . The stock traded as low as $54.07 and last traded at $54.07. 120,819 shares were traded during trading, a decline of 92% from the average session volume of 1,495,266 shares. The stock had previously closed at $55.91. […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) was the recipient of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 10,590,000 shares, a growth of 5.3% from the February 29th total of 10,060,000 shares. Based on an average trading volume of 1,580,000 shares, […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) CFO Timothy Eugene Sullivan sold 4,000 shares of Apellis Pharmaceuticals stock in a transaction on Monday, April 1st. The stock was sold at an average price of $58.66, for a total transaction of $234,640.00. Following the sale, the chief financial officer now directly owns 93,338 shares of […]